Clinical Trial Update: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating olanzapine in combination with a 5-HT3 receptor antagonist, with or without dexamethasone, to prevent chemotherapy-induced n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• 5-HT3 receptor antagonist (5-HT3 receptor antagonist)
• olanzapine (olanzapine)

Snippet

Sponsor: Xingchen Peng | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED